Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA

Modern Rheumatology

Volumn 17, Issue 5, 2007, Pages 403-408

  Shinozaki, Mikiko ^a   Inoue, Eisuke ^a   Nakajima, Ayako ^a   Hara, Masako ^a   Tomatsu, Taisuke ^a   Kamatani, Naoyuki ^a   Yamanaka, Hisashi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Cohort study; HAQ(J HAQ); MMP 3; Rheumatoid arthritis

Indexed keywords

ACTARIT; AURANOFIN; AUROTHIOMALATE; BIOLOGICAL MARKER; BUCILLAMINE; C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; MIZORIBINE; PENICILLAMINE; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; STEROID; STROMELYSIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FUNCTIONAL STATUS; HUMAN; JAPANESE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NORMAL VALUE; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUALITATIVE ANALYSIS; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARTILAGE; COHORT STUDIES; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 35348845697     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-007-0608-5     Document Type: Article

References (14)

1. PE Lipsky DM van der Heijde EW St Clair DE Furst FC Breedveld JR Kalden 2000 Infliximab and methotrexate in the treatment of rheumatoid arthritis N Engl J Med 343 1594-602 11096166 10.1056/NEJM200011303432202 1:CAS:528:DC%2BD3cXovVeltLk%3D
2. MC Genovese JM Bathon RW Martin RM Fleischmann JR Tesser MH Schiff 2002 Etanercept versus methotrexate in patients with early rheumatoid arthritis Arthritis Rheum 46 1443-50 12115173 10.1002/art.10308 1:CAS:528:DC%2BD38Xltlantbk%3D
3. DM van der Heijde M Van't Hof PL Van Riel LAM Theunisse EW Lubberts MA Van Leeuwen 1990 Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of disease activity score Ann Rheum Dis 49 916-20 2256738 1:STN:280:By6D2snmtFQ%3D
4. MLL Prevoo MA van't Hof HH Kuper MA Van Leeuwen LBA Van de Puute PL Van Riel 1995 Modified disease activity scores that include 28 joint counts Arthritis Rheum 38 44-8 7818570 10.1002/art.1780380107 1:STN:280:ByqC3MfjvFI%3D
5. JS Smolen FC Breedveld MH Schiff JR Kalden P Emery G Eberl 2003 A simplified disease activity index for rheumatoid arthritis for use in clinical practice Rheumatology (Oxford) 42 244-57 10.1093/rheumatology/ keg072 1:CAS:528:DC%2BD3sXit1yntLs%3D
6. D Aletaha VP Nell T Stamm M Uffmann S Pflugbeli K Machold 2005 Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score Arthritis Res Ther 7 796-806 10.1186/ar1740
7. S Momohara H Yamanaka MM Holledge T Mizumura K Ikari N Okada 2004 Cartilage oligomeric matrix protein in serum and synovial fluid of rheumatoid arthritis: Potential use as a marker for joint cartilage damage Mod Rheumatol 14 356-60 17143693 10.1007/s10165-004-0323-4 1:CAS:528:DC%2BD2cXpt1ehs78%3D
8. C Ribbens B Andre JM Jaspar O Kaye MJ Kaiser D De Groote 2000 Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis J Rheumatol 27 888-93 10782811 1:CAS:528:DC%2BD3cXivFOrsb4%3D
9. Y Matsuda G Singh H Yamanaka E Tanaka W Urano A Taniguchi 2003 Validation of a Japanese version of the Stanford health assessment questionnaire in 3763 patients with rheumatoid arthritis Arthritis Rheum 49 6 784-8 14673964 10.1002/art.11465
10. H Yamanaka Y Matsuda M Tanaka W Sendo H Nakajima A Taniguchi 2000 Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis Arthritis Rheum 43 852-8 10765930 10.1002/ 1529-0131(200004)43:4<852::AID-ANR16>3.0.CO;2-7 1:CAS:528:DC%2BD3cXivFOitrY%3D
11. MJ Green AK Gough J Devlin J Smith P Astin D Taylor 2003 Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis Rheumatology (Oxford) 42 1 83-8 10.1093/rheumatology/keg037 1:CAS:528:DC%2BD3sXovFamsQ%3D%3D
12. NJ Peake K Khawaja A Myers D Jones TE Cawston AD Rowan 2005 Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: Relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study Rheumatology (Oxford) 44 1383-9 10.1093/rheumatology/ kei025 1:CAS:528:DC%2BD2MXhtFCjtL7N
13. KW Drossaers-Bakker AH Zwinderman TP Vlieland D Van Zeben K Vos FC Breedveld 2002 Long-term outcome in rheumatoid arthritis: A simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup Arthritis Rheum 47 383-90 12209484 10.1002/art.10513 1:STN:280:DC%2BD38vltVCgtQ%3D%3D
14. T Helen AC Dennis 2001 Rheumatoid factor WN Kelley ED Harris Jr S Ruddy CB Sledge Textbooks of rheumatology 6th ed WB Saunders Philadelphia 151-60